公开(公告)号：US20240335413A1

公开(公告)日：2024-10-10

申请号：US18295494

申请日：2023-04-04

申请人： Anthony Beretta

发明人： Anthony Beretta

IPC分类号： A61K31/245 ,  A61K9/00 ,  A61K31/045 ,  A61K31/222 ,  A61K33/30 ,  A61K35/64 ,  A61K36/185 ,  A61K36/534 ,  A61K36/54 ,  A61K47/44

CPC分类号： A61K31/245 ,  A61K9/0014 ,  A61K31/045 ,  A61K31/222 ,  A61K33/30 ,  A61K35/64 ,  A61K36/185 ,  A61K36/534 ,  A61K36/54 ,  A61K47/44

摘要： A method for topically reducing pain and stimulating healing, including providing a homogeneous composition including 15 to 20 weight percent benzocaine, 1 to 2 weight percent menthol, 5 to 15 weight percent zinc oxide, to 10 weight percent octinovate, 1 to 5 weight percent peppermint oil, 0 to 10 weight percent cinnamon oil, 0 to 20 weight percent bee venom, 5 to 20 weight percent cocoa butter, with the balance being nonreactive base matrix material, and then topically applying the homogeneous composition to skin where pain reduction and healing is desired.

公开(公告)号：US20240299332A1

公开(公告)日：2024-09-12

申请号：US18668653

申请日：2024-05-20

申请人： ZHEJIANG YUEJIA PHARMACEUTICALS CO., LTD

发明人： Jing ZHANG

IPC分类号： A61K31/245 ,  A61K9/08 ,  A61K31/216

CPC分类号： A61K31/245 ,  A61K9/08 ,  A61K31/216

摘要： A stable pharmaceutical composition containing a non-steroidal anti-inflammatory drug derivative, at least comprising a separated solid part and liquid part, the solid part comprising a therapeutically effective dose of non-steroidal anti-inflammatory drug derivative and the liquid part being a pharmaceutically acceptable solvent. After a long-term stability study (25° C.±2° C., 12 months), the stability of the solid part was good, and met the requirements of the pharmaceutical industry.

公开(公告)号：US12083184B2

公开(公告)日：2024-09-10

申请号：US18327658

申请日：2023-06-01

申请人： Viking Scientific, Inc.

发明人： Paul Fisher ,  Paulina Davis

IPC分类号： A61K47/69 ,  A61K9/00 ,  A61K9/06 ,  A61K9/14 ,  A61K9/70 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/245 ,  A61K31/522 ,  A61K31/555 ,  A61K31/606 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06 ,  A61K47/08 ,  A61K47/34 ,  A61K47/55 ,  A61K47/59 ,  A61K47/60

CPC分类号： A61K47/6903 ,  A61K9/0019 ,  A61K9/06 ,  A61K9/14 ,  A61K9/7007 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/245 ,  A61K31/522 ,  A61K31/555 ,  A61K31/606 ,  A61K31/675 ,  A61K31/704 ,  A61K45/06 ,  A61K47/08 ,  A61K47/34 ,  A61K47/55 ,  A61K47/59 ,  A61K47/60

摘要： Aspects of the invention described herein include a hydrogel prodrug and methods of making a hydrogel prodrug for drug delivery. Also contemplated are methods of treating, inhibiting, ameliorating or inhibiting a disease or disorder. Without being limiting, the methods for treatment can be directed to a cancer, HIV, a virus, pain, a bacterial infection, a neurological disorder, hemorrhaging, multiple sclerosis, diabetes, high blood pressure, Alzheimer's, or inhibiting a fungal growth in a subject in need.

公开(公告)号：US20240293345A1

公开(公告)日：2024-09-05

申请号：US18569813

申请日：2022-06-14

申请人： Pharmavax AS

发明人： Morten Paulsbo ,  Magnus Paulsbo

IPC分类号： A61K31/167 ,  A61K31/137 ,  A61K31/245 ,  A61K38/095 ,  A61P23/02

CPC分类号： A61K31/167 ,  A61K31/137 ,  A61K31/245 ,  A61K38/095 ,  A61P23/02

摘要： The present invention relates to combinations of local anesthetics for improved pain relief in patients.

公开(公告)号：US20240262916A1

公开(公告)日：2024-08-08

申请号：US18561127

申请日：2022-05-16

申请人： METANOIA BIO INC.

发明人： Slavica TUDZAROVA-TRAJKOVSKA ,  Oppel GREEFF ,  Abraham VAN WYK

IPC分类号： C07K16/28 ,  A61K31/196 ,  A61K31/198 ,  A61K31/245 ,  A61K31/26 ,  A61K31/352 ,  A61K31/357 ,  A61K31/37 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/519 ,  A61K31/661 ,  A61K38/06 ,  A61K38/08 ,  C12N15/113

CPC分类号： C07K16/2857 ,  A61K31/196 ,  A61K31/198 ,  A61K31/245 ,  A61K31/26 ,  A61K31/352 ,  A61K31/357 ,  A61K31/37 ,  A61K31/381 ,  A61K31/403 ,  A61K31/41 ,  A61K31/416 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/498 ,  A61K31/501 ,  A61K31/519 ,  A61K31/661 ,  A61K38/06 ,  A61K38/08 ,  C12N15/1138 ,  C07K2317/569 ,  C12N2310/11

摘要： The disclosure provides methods and compositions for treating cardiovascular disease with HIF1-a Pathway Inhibitors and PFKFB3 Inhibitors. Exemplary cardiovascular diseases ns treated using the provided methods and compositions include acute coronary syndrome, coronary artery disease, myocardial infarction, coronary heart disease, carditis or cardiomyopathy, an ischemic cardiovascular disease, heart failure, stroke, peripheral vascular disease peripheral arterial disease, and ischemia/reperfusion injury.

公开(公告)号：US11969442B1

公开(公告)日：2024-04-30

申请号：US18219526

申请日：2023-07-07

申请人： KING FAISAL UNIVERSITY

发明人： Hany Mohamed Abd El-Lateef Ahmed ,  Saadeldin Elsayed Ibrahim Shabaan ,  Jihad Wadai Saleh Alessa

IPC分类号： A61K33/26 ,  A61K9/12 ,  A61K31/245 ,  A61K36/14 ,  A61K36/54 ,  A61K47/46

CPC分类号： A61K33/26 ,  A61K9/12 ,  A61K31/245 ,  A61K36/14 ,  A61K36/54 ,  A61K47/46

摘要： Covid-19 binding aerosols are provided. The Covid-19 binding aerosols include Fe3O4 microparticles, at least one organoselenium compound, at least one essential oil, and incense. The Covid-19 binding aerosols may be formulated for use in any product that is capable of emitting aerosols, including but not limited to as air fresheners, as incense, or the like. The Fe3O4 microparticles may have an average size of 5,000 nm-10,000 nm (between 5-10 μm). The Covid-19 binding aerosols are formulated as aerosol compositions having an average size of greater than 60 μm-100 μm to ensure effective binding to virions.

公开(公告)号：US11951082B2

公开(公告)日：2024-04-09

申请号：US18198369

申请日：2023-05-17

申请人： Jacques Ford

发明人： Jacques Ford

IPC分类号： A61K31/155 ,  A61K9/00 ,  A61K31/047 ,  A61K31/245 ,  A61K31/573

CPC分类号： A61K31/155 ,  A61K9/0014 ,  A61K31/047 ,  A61K31/245 ,  A61K31/573

摘要： The present invention is directed to a medicinal composition, and more particularly, to a composition of chlorhexidine to treat lesions, particularly lesions caused by cold sores and herpes. The composition comprises chlorhexidine as the active ingredient. The composition also comprises a component for pain relief and a component for anti-inflammation. These three components, which act efficaciously in concert, are then combined with a suitable emollient or vehicle to form a topical formulation effective to treat the symptoms of cold sores and herpes. The composition may be formulated as an over-the-counter (OTC) topical formulation.

公开(公告)号：US20240074994A1

公开(公告)日：2024-03-07

申请号：US18198369

申请日：2023-05-17

申请人： Jacques Ford

发明人： Jacques Ford

IPC分类号： A61K31/155 ,  A61K9/00 ,  A61K31/047 ,  A61K31/245 ,  A61K31/573

CPC分类号： A61K31/155 ,  A61K9/0014 ,  A61K31/047 ,  A61K31/245 ,  A61K31/573

摘要： The present invention is directed to a medicinal composition, and more particularly, to a composition of chlorhexidine to treat lesions, particularly lesions caused by cold sores and herpes. The composition comprises chlorhexidine as the active ingredient. The composition also comprises a component for pain relief and a component for anti-inflammation. These three components, which act efficaciously in concert, are then combined with a suitable emollient or vehicle to form a topical formulation effective to treat the symptoms of cold sores and herpes. The composition may be formulated as an over-the-counter (OTC) topical formulation.

公开(公告)号：US11890422B2

公开(公告)日：2024-02-06

申请号：US18144043

申请日：2023-05-05

申请人： PFOF LLC

发明人： Howard L. Howell ,  Ralf Blackstone

IPC分类号： A61M19/00 ,  A61M5/19 ,  A61M5/14 ,  A61K31/445 ,  A61K31/245 ,  A61K47/02 ,  A61K31/167

CPC分类号： A61M19/00 ,  A61K31/167 ,  A61K31/245 ,  A61K31/445 ,  A61K47/02 ,  A61M5/1408 ,  A61M5/19 ,  A61M2205/05

摘要： An improved anesthetic nerve block and method is disclosed comprising a dispenser including a storage body, a transfer body and a tip for positioning adjacent to the nerve. A local short acting anesthetic is in the storage body. A physiologic carbonate base is in the storage body. The local short acting anesthetic and the physiologic carbonate base are dispensed from the tip of the dispenser where the local short acting anesthetic facilities the penetration of the physiologic carbonate base through the nerve membrane and into the axon. A local long acting anesthetic is in the storage body. The local long acting anesthetic is dispensed from the tip of the dispenser and penetrates through the nerve membrane and into the axon. The local long acting anesthetic and the physiologic carbonate base cause a precipitate and form a crystallization compound for creating a prolonged local nerve block.

公开(公告)号：US11890267B2

公开(公告)日：2024-02-06

申请号：US17573333

申请日：2022-01-11

申请人： Tris Pharma Inc.

发明人： Andrea Nelson ,  Quin-Zene Chen ,  Harsh Mehta ,  Yu-Hsing Tu

IPC分类号： A61K9/20 ,  A61K31/245 ,  A61K9/00 ,  A61K9/24 ,  A61K9/28 ,  A61K31/09 ,  A61K31/25 ,  A61K45/06 ,  A61K9/50

CPC分类号： A61K31/245 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/209 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/09 ,  A61K31/25 ,  A61K45/06 ,  A61K9/2013 ,  A61K9/5084 ,  A61K31/245 ,  A61K2300/00 ,  A61K31/09 ,  A61K2300/00

摘要： A modified release benzonatate solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.